KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Revenue (2016 - 2026)

Biocryst Pharmaceuticals filings provide 16 years of Revenue readings, the most recent being $708000.0 for Q4 2025.

  • On a quarterly basis, Revenue fell 99.46% to $708000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $469.0 million, a 4.06% increase, with the full-year FY2025 number at $874.8 million, up 94.1% from a year prior.
  • Revenue hit $708000.0 in Q4 2025 for Biocryst Pharmaceuticals, down from $159.4 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $163.4 million in Q2 2025 to a low of $708000.0 in Q4 2025.
  • Median Revenue over the past 5 years was $81.0 million (2022), compared with a mean of $84.0 million.
  • Biggest five-year swings in Revenue: skyrocketed 1640.13% in 2021 and later plummeted 99.46% in 2025.
  • Biocryst Pharmaceuticals' Revenue stood at $47.2 million in 2021, then surged by 68.68% to $79.5 million in 2022, then rose by 17.42% to $93.4 million in 2023, then soared by 40.83% to $131.5 million in 2024, then plummeted by 99.46% to $708000.0 in 2025.
  • The last three reported values for Revenue were $708000.0 (Q4 2025), $159.4 million (Q3 2025), and $163.4 million (Q2 2025) per Business Quant data.